MENU
AKLI
AS OF
Jul 8 closing price
Price
$0.43
Change
-$0.00 (-0.00%)
Capitalization
21.9M
Go to the list of all blogs
Akili (AKLI, $1.03) gets Equal Weight rating from Morgan Stanley
Morgan Stanley initiated coverage on Akili Inc. with a rating of Equal Weight and a price target of $2 on the stock.
According to the analyst, the digital medicine company’s product EndeavorRx could generate more than $200 million in peak sales in ADHD. EndeavorRx got marketing authorization from the FDA in mid-2020 as a medical device for patients aged 8-12 with ADHD, and a commercial launch began in late 2022.
The analyst indicated that given the apparent skepticism of the market for digital therapeutics’ sales potential, a significant focus on early launch metrics such as script growth and refill rates is expected.
Akili’s pivotal data in ADHD patients aged 13-17 and 18+ is likely in the second half of 2023.
Related Ticker: AKLI
View a ticker or compare two or three
VS
VS
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry PackagedSoftware
Profile
Fundamentals
Details
Industry
N/A
Address
71 Commercial Street
Phone
+1 617 313-8853
Employees
68
Web
https://www.akiliinteractive.com
Ad is loading...